Nous ne pouvons afficher que des informations limitées pour ce cabinet. Nous affichons des informations plus complètes pour les cabinets suivants :
Covington & Burling LLP stands out for its 'truly unique expertise and experience in the topic of national and multilateral benefit-sharing for pathogens'. The team is well known for its strength in handling EU pharmaceutical regulatory issues and reimbursement procedures. Peter Bogaert is highly regarded for his extensive experience in advising on matters concerning medical devices and biotech issues; he co-heads the practice with Bart Van Vooren, who routinely appears before the CJEU and the EGC in contentious matters involving clinical trials' data.
L’éditorial du Legal 500
Témoignages
Collectés indépendamment par l'équipe de recherche du Legal 500.
‘Good reputation.’
‘Covington has truly unique expertise and experience in the topic of national and multilateral benefit-sharing for pathogens. They bring together an incredible source of expertise. Working with them is really easy and straightforward and the team is just amazing.'
Clients clés
- AbbVie
- AstraZeneca
Points forts
- Representing Aloe Vera of Europe in ongoing litigation before the EU General Court, including a request for suspension, against a Commission Regulation banning HADs, a substance that is found naturally in most plants, for an infringement of the precautionary principle.
- Advising EUCOPE on a range of matters, including regulatory data protection, pricing and market access, transparency, pediatrics, and the revision of the orphan medicines regime.